Das Medizinportal     Aktuelles für medizinische Fachkreise
Menü

Das Medizinportal     Aktuelles für medizinische Fachkreise

Literatur:

Liquid Biopsy beim Kolonkarzinom: Optimierung der Diagnostik und des Therapiemonitorings

Alexander Baraniskin, Wolff Schmiegel Medizinische Klinik, Universitätsklinikum Knappschaftskrankenhaus Bochum

  1. Datenbank des Robert-Koch-Instituts
  2. Alberts SR: Update on the optimal management of patients with colorectal liver metastases. Crit Rev Oncol Hematol 2012 Oct; 84(1):59–70
  3. Peeters et al. Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC). J Clin Oncol 32, 2014 (suppl 3; abstr LBA387)
  4. Gerlinger et al. Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing. N Engl J Med 2012; 366:883–892
  5. Inger Marie Løes et al. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases. Int J Cancer 2016 Mar 16. doi: 10.1002/ijc.30089
  6. Lee KH, Kim JS, Lee CS, Kim JY. KRAS discordance between primary and recurrent tumors after radical resection of colorectal cancers. J Surg Oncol. 2015 Jun; 111(8):1059–64
  7. Siyar Ekinci A , Demirci U, Cakmak Oksuzoglu B et al. KRAS discordance between primary and metastatic tumor in patients with metastatic colorectal carcinoma. J BUON. 2015 Jan–Feb; 20(1):128–35
  8. Dressmann et al. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci USA 2003 Jul 22; 100(15):8817–22
  9. Hahn S et al. Eur J Cancer 2015; 51(suppl 3):S79
  10. Diehl F et al Circulating mutant DNA to assess tumor dynamics. NatureMed 2008, 14: 985–90
  11. Schwarzenbach H, Dave S. B. Hoon & Klaus Pantel Cell-free nucleic acids as biomarkers in cancer patients Nature Reviews Cancer June 2011; 11, 426–37
  12. Bettegowda C et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014; 6:224ra24
  13. Van Emburgh BO, Arena S, Siravegna G, et al. Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. Nat Commun 2016 Dec 8; 7:13665
  14. Morelli et al, Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Annals of Oncology 2015; 26:731–36 
  15. Toledo RA, Cubillo A, Vega E, et al. Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab. Oncotarget 2016 Nov 11; doi:10.18632/oncotarget.13311
  16. Siravegna et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nature Medicine 2015; 21:795–801

Onkologische Kolorektalchirurgie bei Patienten mit Übergewicht und Adipositas

Sylvia Weiner, Stefan Berkhoff; Krankenhaus Nordwest Frankfurt

  1. Bundesgesundheitsbl 2013; 56:786–94; DOI 10.1007/s00103-012-1656-3 Online publiziert: 27. Mai 2013 © Springer-Verlag Berlin Heidelberg 2013
  2. WHO Fact sheet N°311
  3. DIMDI (2015): ICD-10_GM-Version 2015. Internationale statistische Klassifikation der Krankheiten und verwandter Gesundheitsprobleme. 10. Revision, Deutsches Institut für Medizinische Dokumentation und Information
  4. Mensink G.B.M. et al. Abteilung für Epidemiologie und Gesundheitsmonitoring, Robert Koch-Institut, Berlin: Übergewicht und Adipositas in Deutschland; Ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1)
  5. S3-Leitlinie „Therapie und Prävention der Adipositas – AWMF-Letlinien
  6. 6.         S. Klein, S. Krupka, S. Behrendt, A. Pulst, H.H. Bleß: Weißbuch Adipositas 2016.   Medizinisch Wissenschaftliche Verlagsgesellschaft 2016
  7. Webber L, Divajeva D, Marsh T et al. The future burden of obesity-related diseases in the 53 WHO European-Region countries and the impact of effective interventions: a modelling study. BMJ Open 2014 Jul 25; 4(7):e004787
  8. Schulz MD, Atay C, Heringer J. et al. High-fat diet-mediated dysbiosis promotes intestinal carcinogenesis independent of obesity. Nature 2014 October 23; 514(7523):508–12; doi:10.1038/nature13398
  9. Giovannucci E, Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas.Gastroenterology 2007; 132:2208–25
  10. Wu GD, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science 2011; 334:105–08
  11. Schwabe RF, Jobin C. The microbiome and cancer. Nat Rev Cancer 2013; 13:800–12
  12. Gilbert W. Kim, Jieru E. Lin, and Scott A. Waldman. GUCY2C: at the intersection of obesity and cancer. Trends Endocrinol Metab 2013 April; 24(4):165–73
  13. Rahbi H, et al. The uroguanylin system and human disease. Clinical science. 2012; 123:659–68
  14. Lenard NR, Berthoud HR. Central and peripheral regulation of food intake and physical activity: pathways and genes. Obesity (Silver Spring) 2008; 16(Suppl 3):S11–22
  15. Masoomi H, Nguyen NT, Stamos MJ, Smith BR. Overview of outcomes of laparoscopic and open Roux-en-Y gastric bypass in the United States. Surg Technol Int 2012 Dec; 22:72–76
  16. Nguyen NT. Open vs. laparoscopic procedures in bariatric surgery. J Gastrointest Surg 2004 May–Jun; 8(4):393–95
  17. Bonjer, HJ, Deijen CL, Abis GA et al. A randomized trial of laparoscopic versus open surgery for rectal cancer. New England J of Med 2015
  18. Balentine CJ, Marshall C, Robinson C, Wilks J, Anaya D, Albo D et al. Obese patients benefit from minimally invasive colorectal cancer surgery. J Surg Res 2010; 163(1):29–34
  19. Shang E, Beck G: Anästhesie bei Adipositas. Besonderheiten bei bariatrischer Chirurgie
  20. Anasthesiol Intensivmed Notfallmed Schmerzther 2009: 44(9):612–18
  21. Schwenk W, Spies C, Müller M: Beschleunigte Frührehabilitation in der operativen Medizin
  22. Deutsches Ärzteblatt (2005); 102; 21:A1514–20
  23. Benlice C, Aytac E, Costedio M, Kessler H, Abbas MA, Remzi FH, Gorgun E. Robotic, laparoscopic, and open colectomy: a case-matched comparison from the ACS-NSQIP. Int J Med Robot 2016 Oct 21. doi: 10.1002/rcs.1783
  24. Jiménez-Rodríguez RM et al. Learning curve in robotic rectal cancer surgery: current state of affairs. Int J Colorectal Dis 2016 Dec; 31(12):1807–15

Moderne medikamentöse Therapieoptionen

Sebastian Stintzing, Volker Heinemann; Medizinische Klinik mit Poliklinik III, Klinikum der Universität München (LMU)

 

  1. Robert-Koch-Institut R-K.: Bericht zum Krebsgeschehen in Deutschland  2016
  2. Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016; 27(8):1386–422.
  3. NCCN Guidelines Colon Cancer Version 1, 2017 [Internet]
  4. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008; 26(12):2013–9
  5. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23):2335–42
  6. Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011; 29(15):2011–19
  7. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013; 369(11):1023–34
  8. Stintzing S, Modest DP, Rossius L, Lerch MM, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet Oncol 2016
  9. Schwartzberg LS, Rivera F, Karthaus M, G. F, Canon JL, Hecht JR, et al. PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer. Journal of Clinical Oncollogy. 2014; Published online before print March 31, 2014
  10. Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Mahony M, O'Neil B, et al. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol 2014; 32:5s, 2014 (suppl; abstr LBA3)
  11. Holch J, Stintzing S, Heinemann V. Treatment of Metastatic Colorectal Cancer: Standard of Care and Future Perspectives. Visc Med. 2016; 32(3):178–83
  12. Rowland A, Dias MM, Wiese MD, Kichenadasse G, McKinnon RA, Karapetis CS, et al. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer. 2015; 112(12):1888–94
  13. Pietrantonio F, Petrelli F, Coinu A, Di Bartolomeo M, Borgonovo K, Maggi C, et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer. 2015; 51(5):587–94
  14. Stintzing S, Heinemann V. FIRE-4.5-Studie. FORUM 2017
  15. Tejpar S, Stintzing S, Ciardiello F, Tabernero J, Van Cutsem E, Beier F, et al. Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials. JAMA Oncol. 2016
  16. Boeckx N, Toler A, Op de Beeck K, Kafatos G, Deschoolmeester V, Rolfo C, et al. Primary tumor sidedness impacts on prognosis and treatment outcome: results from three randomized studies of panitumumab plus chemotherapy versus chemotherapy or chemotherapy plus bevacizumab in 1st and 2nd line RAS/BRAF WT mCRC. Annals of Oncology 2016; 27 (Supplement 6):vi1–vi14
  17. Venook A, D. N, Innocenti F, Fruth B, Greene C, O'Neil BH, et al. Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol 2016; 34(suppl; abstr 3504)
  18. Brule SY, Jonker DJ, Karapetis CS, O'Callaghan CJ, Moore MJ, Wong R, et al. Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. Eur J Cancer. 2015; 51(11):1405–14
  19. Holch JW, Ricard I, Stintzing S, Modest DP, Heinemann V. The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. Eur J Cancer. 2017; 70:87–98
  20. www.aio-portal.de/index.php/stellungnahmen.html
  21. Hegewisch-Becker S, Graeven U, Lerchenmuller CA, Killing B, Depenbusch R, Steffens CC, et al. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol. 2015; 16(13):1355–69
  22. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007; 25(12):1539–44
  23. Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van Cutsem E, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013; 14(1):29–37
  24. Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausova J, Macarulla T, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012; 30(28):3499–506
  25. Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015; 16(5):499–508
  26. Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015; 372(20):1909–19
  27. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013; 381(9863):303–12
  28. Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016; 17(6):738–46
  29. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015; 372(26):2509–20

UPDATE

Management Update 2017: Venöse Thromboembolien bei Tumorpatienten

Cecilia Bozzetti, Hanno Riess; Medizinische Klinik, Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie, Universitätsmedizin Berlin

  1. Kearon C, Akl EA, Ornelas J et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report.Chest 2016; 149:315–52
  2. Farge D, Bounameaux H, Brenner B et al, International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer.Lancet Oncol. 2016;17:e452–e66
  3. Riess H, Habbel P, Jühling A et al. Primary prevention and treatment of venous thromboembolic events in patients with gastrointestinal cancers World J Gastrointest Oncol. 2016; 8(3):258–70
  4. Fallanga A Marchetzti M, Russo L. The mechanisms of cancer-associated thrombosis. Thromb Res 2015; 135:S8–11
  5. Timp JF, Braekkan SK, Versteeg HH et al. Epidemiology of cancer associated venous thrombosis. Blood 2013; 122:1712–1723
  6. Khorana AA, Otten HM, Zwicker JI et al. for the subcommittee on Haemostasis and Malignancy. Prevention of venous thromboembolism in cancer outpatients: guidance from the SSC of the ISTH.  Journal of Thrombosis and Haemostasis, 12:1928–31
  7. Palumbo A, Rajkumar SV, Dimopoulos MA et al.: Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22:414–23
  8. Decousus H, Bertoletti I Frappe P, et al. Recent findings in epidemiology, diagnosis and treatment of superficial vein thrombosis. Thromb Res2011; 127:S81–85
  9. Haas S, Encke A, Kopp I.German S3 practice guidelines on prevention of venous thromboembolism--New and established evidence.Dtsch Med Wochenschr. 2016; 141:453–56
  10. Ellis MH, Fajer S. A current approach to superficial vein thrombosis. Eur J Haematol 2012; 90:85–88
  11. Decousus H, Prandoni P, Mismett P et al. for the CosiCALISTO Study Group. Fondaparinux for the treatment of superficial-vein thrombosis in the legs N Engl J Med, 2010; 363:1222–32
  12. Cosmi B, Filipini M, Tonti J et al. A randomized double-blind study of low molecular weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX. J Thromb Haemost 2012; 10:1026–35
  13. Vedovati MC, Germini F, Agnelli G,Becattini C. Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis.Chest. 2015; 147:475–83
  14. Francis CW, Kessler CM, Goldhaber SZ et al. Trearment of venous thromboembolism in cancer patients, with dalteparin for up to 12 months: the DALTECAN study. J Thromb Haemost 2015; 13:1028–35
  15. Romualdi E, Ageno W.Management of recurrent venous thromboembolism in cancer patients. Thromb Res. 2016; 140:S128–31
  16. Lee AY. Thrombosis in cancer: an update on prevention, treatment and survival benefits of anticoagulants. Am Soc Hematol Educ Program 2010; 2010:144–49
  17. Di Niso M, Lee AYY, Carrier M et al. for the subcommittee on Haemostasis and Malignancy. Diagnosis and treatment of incidental venous thromboembolism in cancer patients: guidance from the SSC of the ISTH. J Thromb Haemosts, 2015; 13:880–83
  18. Murray J, Precious E, Alikhan R. Catheter-related Thrombosis in cancer patients. Brit J Haematol 2013; 162:748–57
  19. Saccullo G, Marietta M, Carpenedo M et al. Platelet cut-off for anticoagulant therapy in cancer patients with venous thromboembolism and thrombocytopenia: an expert opinion based on RAND/UCLA appropriateness method (RAM). ASH 2013 Blood 2013; 122:581
  20. Wun T, White RH. Venous thromboembolism (VTE) in patients with cancer: epidemiology and risk factors. Cancer Invest. 2009; 27(S1):63–74. doi: 10.1080/07357900802656681
  21. Carrier M, Prandoni P. Controversies in the management of cancer-associated thrombosis. Expert Rev Hematol. 2017 Jan; 10(1):15–22. doi:10.1080/17474086.2017.1257935